Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C

Hepato-Gastroenterology

Volumn 44, Issue 16, 1997, Pages 1182-1186

  Laghi, Vittorio ^a   Toccaceli, Fabrizio ^a   Rosati, Silvia ^a   Monini, Antonella ^a   Grimaldi, Maria ^b   Foglianti, Gianni ^b   Canova, Nadia ^b   Palazzini, Ernesto ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Gamma glutamyltranspeptidase; Hepatitis C viruses; Hepatitis chronic active; Natural interferon alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0030803372     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tremolada F, Benvegnv̀ L, Casarin C, Pontisso P, Tagger A, Alberti A. Antibody to hepatitis C virus in hepatocellular carcinoma. Lancet 1990; 335:300-301.
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992; 327:1899-1905.
3. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14:969-974.
4. Kiyosawa K, Sodeyama T, Tanaka E at al. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.
5. Simonetti RG, Cammà C, Fiorello F et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-controlled study. Ann Intern Med 1992; 116:97-102.
6. Goeser T, Theilmann L. Review. Therapy of chronic viral hepatitis. Int J Clin Pharmacol Ther, 1994; 32:571-576.
7. Romeo R, Rumi M, Colombo M. Alpha interferon treatment of chronic hepatitis C. Biomed Pharmacother 1995; 49:111-115.
8. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med, 1989; 321:1501-1506.
9. Sherlock S. Antiviral therapy for chronic hepatitis C viral infection. J Hepatol, 1995; 23:3-7.
10. Jacyna MR, Brooks MG, Look RHT et al. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J, 1989; 298:80-88.
11. Saracco G, Rizzetto M. The long-term efficacy of interferon alfa in chronic hepatitis C patients: A critical review. J Gastroenterol Hepatol, 1995; 10:668-673.
12. Rumi MG, Del Ninno E, Parravicini ML et al. Long-term titrated recombinant interteron-α2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepatitis, 1995; 2:73-76 .
13. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon-α2b. Hepatology 1993, 181300-1305.
14. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha -2a-Interferon in Chronic Hepatitis C. Hepatology, 1995; 22:700-706.
15. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330:143 .
16. Yoshioka A, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16:293-299.
17. Chemello L, Cavalletto L, Noventa F, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-α Viral Hepat, 1995, 2:91-96.
18. Davis LG. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol, 1994; 21:1-3.
19. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology, 1995; 21:291-297.
20. Iino S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high dose interferon-α2b. A multicenter study. Dig Dis Sci 1993; 38:612-618.
21. Negro F, Baldi M, Mondardini A, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alpha-2a. Gastroenterology 1994; 107:479-485.
22. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1981; 1:431-435.
23. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group. J Hepatol, 1990; 11:S63-7.
24. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol, 1996; 24:141-147.
25. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic hepatitis C with cirrhosis. Lancet, 1995; 346:1051-1055.
26. Alberti A., Chemello L., Bonetti P, et al. Treatment with interferon(s) of community- acquired chronic hepatitis and cirrhosis type C. J Hepatol, 1993; 17:S123-126.
27. Casarin C, Chemello L, Bonetti P, et al. Comparison of different types and doses of alpha IFN for treatment of chronic hepatitis C. J Hepatol, 1994; 21 S62.
28. Iino S. High dose interferon treatment in chronic hepatitis C. Gut 1993; 34 (2):S114-18.
29. Lindsay KL, Davis GL, Schiff E, et al. Long-term response to higher doses of interferon (IFN) alfa-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1993; 18:106A.
30. Benelux Multicentre Trial Study Group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard versus high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; 34:S119-S120.
31. Realdi G., Diodati G, Bonetti P. et al. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol, 1990; 11:S68-S71.
32. Tinη; F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol, 1991; 13:192-199.
33. Van Thiel DH, Friedlander L, Malloy P, et al. Glutamyl Transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterology, 1995; 42:888-892.
34. Viscomi GC, Grimaldi M, Palazzini E, Silvestri S. Human leukocyte interferon alpha: structure, pharmacology and therapeutic applications. Medic Res Rev, 1995; 15:445-478.